146 results on '"Adams, Hugo J.A."'
Search Results
2. Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis
3. Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients
4. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma
5. Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy
6. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis
7. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma
8. Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma
9. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma
10. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
11. 18F-FDG-PET is not a useful tool for end-of-treatment response evaluation in peripheral T-cell lymphomas
12. Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?
13. A negative 18F-FDG-PET scan can never exclude residual disease
14. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
15. Assessing baseline bone marrow status in advanced-stage Hodgkin lymphoma: does it have any purpose?
16. Increased bone marrow FDG uptake at PET/CT is not a sufficient proof of bone marrow involvement in diffuse large B-cell lymphoma
17. False-negative FDG-PET in histologically proven extensive large cell bone marrow involvement in diffuse large B-cell lymphoma
18. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric–metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma
19. Pagetʼs disease of the bone mimicking lymphomatous bone marrow involvement at FDG-PET
20. Critical considerations on the utility of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for posttreatment restaging of the bone marrow in diffuse large B-cell lymphoma
21. Bone marrow 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma
22. Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy
23. Chest CT Imaging Signature of COVID-19 Infection
24. Response
25. Inability of Fluorodeoxyglucose Positron Emission Tomography to Detect Viable Hodgkin Lymphoma During and After Treatment
26. Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients
27. Only a Small Proportion of Patients With Early-Stage Hodgkin Lymphoma May Potentially Benefit From Fluorodeoxyglucose-Positron Emission Tomography–Adapted Treatment Escalation
28. Value of detecting bone marrow involvement in Hodgkin lymphoma
29. A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma
30. Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed
31. A Pitfall for Diffusion-weighted MR Imaging When Assessing the Response to Neoadjuvant Chemotherapy in Ewing Sarcoma
32. Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma
33. Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma
34. Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography–Adapted Treatment in Advanced-Stage Hodgkin Lymphoma
35. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma
36. Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma
37. Interim Fluorodeoxyglucose Positron Emission Tomography–Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma
38. Guest Editorial on PET of Benign Musculoskeletal Conditions
39. Radiation-Induced Giant Cell Granuloma Mimicking Relapsed Hodgkin Lymphoma at FDG-PET/CT
40. Radiation-Induced Giant Cell Granuloma Mimicking Relapsed Hodgkin Lymphoma at FDG-PET/CT
41. Overestimated Value of Baseline Total Metabolic Tumor Volume at 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography in Follicular Lymphoma
42. Reply: Interim PET in Hodgkin Lymphoma: Is It So Useless?
43. In Regard to Ceriani et al
44. Predictive Value of Interim [18F]Fluorodeoxyglucose–Positron Emission Tomography in Advanced-Stage Hodgkin Lymphoma Is Not Well Established
45. Fact Sheet About Interim and End-of-Treatment 18F-FDG PET/CT in Lymphoma
46. Hodgkin lymphoma: is there really a need for interim and end‐of‐treatmentFDG‐PETevaluations?
47. The Need for Prudence When Using 18F-FDG PET as a Reference Standard for Lymphoma Detection
48. Neither Posttreatment PET/CT Nor Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma
49. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis
50. Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL—Letter
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.